Sialic acid is a marker of lung injury following lower extremities ischemia/reperfusion

European Journal of Vascular and Endovascular Surgery

Volumn 27, Issue 5, 2004, Pages 553-558

  Berkan, O ^a   Gol M K ^b   Icagasioglu S ^a   Cetinkaya O ^a   Yildiz, E ^a   Dogan K ^a   Gunay I ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Lung injury; Sialic acid; Torso ischemia and reperfusion; Tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; DEXAMETHASONE; PENTOXIFYLLINE; SIALIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA CLAMPING; ARTERIAL BLOOD; ARTICLE; BLOOD GAS ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HISTOLOGY; LEG ISCHEMIA; LUNG INJURY; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RAT; RAT STRAIN; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 11144355792     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2004.02.006     Document Type: Article

References (18)

1. Ng S, Dain JA, Rosenburg A, Schengrund C, York J. The natural occurrence of sialic acids. In: Rosenburg A, Schengrund C, eds. Biological role of sialic acid. New York: Plenum, 1976: 90-102.
2. Gavella M, Lipovac V. Erythrocyte sialic acid alterations in experimental diabetes. Cell Mol Biol 1985; 31:75-80.
3. Allain F, Olivier E, Le-Bouil A, Benoit C, Geslin P, Tadei A. Increase of sialic acid concentration in the plasma of patients with coronary disease. Presse-Med 1996; 25:96-98.
4. Berkan O, Sagban M. Sialic acid, or troponin t to detect perioperative myocardial damage in patients undergoing elective coronary artery bypass grafting. Circ J 2002; 66:1019-1023.
5. Crook M, Haq M, Haq S, Tutt P. Plasma sialic acid and acute-phase proteins in patients with myocardial infarction. Angiology 1994; 45:709-715.
6. Berkan O, Gol MK, Gunay L, Sagaban M. Sialic acid is an indicator of inflammation due to cardiopulmonary bypass but not myocardial damage. J Cardiovasc Surg (Torino) 2002; 43(4): 489-493.
7. Gaines GC, Welborn B, Moldawer LL, Huber TS, Harward TR, Seeger JM. Attenuation of skeletal muscle ischemia/ reperfusion injury by inhibition of tumor necrosis factor. J Vasc Surg 1999; 29:370-376.
8. Strenberg WC, Tuttle TM, Makhoul RG, Bear HD, Sobel M, Fowler AA. Postischemic extremities exhibit immediate release of tumor necrosis factor. J Vasc Surg 1994; 20:474-481.
9. Khimenko P, Bagby G, Fuseler J, Taylor A. Tumor necrosis factor-alpha in ischemia and reperfusion injury in rat lung. J Appl Physiol 1998; 85:2005-2011.
10. Colletti L, Cortis A, Lukacs N, Kunkel S, Green M, Strieter R. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998; 10:182-191.
11. Tassiopoulos A, Carling RE, Gao Y, Pedoto A, Finck CM, Landas SK, Tice DG, Marx W, Hakim TS, McGraw DJ. Role of nitric oxide and tumor necrosis factor on lung injury caused by ischemia reperfusion of the lower extremities. J Vasc Surg 1997; 26:647-656.
12. Sullivan GW, Carper HT, Novick Jr. WJ, Mandell GL. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxyfilline. Infect Immun 1988; 56:1722-1729.
13. Irie K, Fujii E, Ishida H, Wada K, Suganuma T, Nishikori T, Yoshioka T, Muraki T. Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin. Br J Pharmacol 2001; 133: 237-242.
14. Kim NY, Pae HO, Kim YC, Choi CK, Rim JS, Lee HS, Kim YM, Chung HT. Pentoxifylline potentiates nitric oxide production in interleukin-1beta-stimulated vascular smooth muscle cells through cyclic AMP-dependent protein kinase a pathway. Gen Pharmacol 2000; 35(4):205-211.
15. Tassiopoulos A, Hakim T, Finck C, Pedoto A, Hodell M, Landas S, McGraw D. Neutrophil sequestration in the lung following acute aortic occlusion starts during ischaemia and can be attenuated by tumour necrosis factor and nitric oxide blockade. Eur J Vasc Endovasc Surg 1998; 16:36-42.
16. Sheridan BC, Mc Intyre RC, Meldrum DR, Fullerton DA. Pentoxifylline treatment attenuates pulmonary vasomotor dysfunction in acute lung injury. J Surg Res 1997; 71:150-154.
17. Lindsey HJ, Kisala JM, Ayala A, Lehman D, Herdon CD, Chaudry IH. Pentoxifylline attenuates oxygen-induced lung injury. J Surg Res 1994; 56:543-548.
18. Welbourn R, Goldman G, O'Riordian M, Lindsay TF, Paterson IS, Kobzik L, Valeri CR, Shepro D, Hechtman HB. Role for tumor necrosis factor as mediator of lung injury following lower torso ischemia. J Appl Physiol 1991; 70: 2645-2649.